Dergiler / Bezmiâlem Science / 2018 / Cilt: 6 - Sayı: 2

Development of Hyperprolactinemia Induced by the Addition of Bupropion to Venlafaxine XR Treatment

Venlafaksin XR Tedavisine Bupropion Eklenmesiyle Gelişen Hiperprolaktinemi Olgusu

Sayfa
150–152
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Here, we present the case of a patient diagnosed with depressive disorder and receiving venlafaxine, who developed hyperprolactinemia and oligomen- orrhea after the addition of bupropion the ongoing treatment and showed serum prolactin levels decreased to normal ranges shortly after the discontinuation of bupropion.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Hyperprolactinemia is characterized by abnormally increased serum prolactin levels.
📊
Temel Bulgular & Veri:Menstrual irregularities and hyperprolac- tinemia can be caused by a variety of medical conditions as well as due to the use of some psychopharmacological drugs, namely antipsychotics; it can also develop during antidepressant treat- ment.
💡
Sonuç & Katkı:Here, we present the case of a patient diagnosed with depressive disorder and receiving venlafaxine, who developed hyperprolactinemia and oligomen- orrhea after the addition of bupropion the ongoing treatment and showed serum prolactin levels decreased to normal ranges shortly after the discontinuation of bupropion.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Hyperprolactinemia is characterized by abnormally increased serum prolactin levels. Menstrual irregularities and hyperprolac- tinemia can be caused by a variety of medical conditions as well as due to the use of some psychopharmacological drugs, namely antipsychotics; it can also develop during antidepressant treat- ment. Bupropion is an antidepressant functioning via the inhi- bition of noradrenaline and dopamine reuptake. The endocrine and sexual adverse events of this agent are rare. In the litera- ture, only one case reporting hyperprolactinemia or galactorrhea caused by bupropion use is available. Here, we present the case of a patient diagnosed with depressive disorder and receiving venlafaxine, who developed hyperprolactinemia and oligomen- orrhea after the addition of bupropion the ongoing treatment and showed serum prolactin levels decreased to normal ranges shortly after the discontinuation of bupropion.

Abstract

Hiperprolaktinemi kandaki prolactin düzeyinin anormal yük- sek olması durumuna denir. Menstrüasyon düzensizlikleri ve hiperprolaktinemi pek çok tıbbi duruma ve psikofarmakolojik ilaçlardan daha çok antipsikotik ajanlara bağlı olabileceği gibi an- tidepresanların kullanımı sonucunda da görülmektedir. Bupro- pion ise noradrenalin ve dopamine gerialım inhibisyonu yoluyla etki eden antidepresan bir ajandır. Bu ajanın endokrin ve cinsel yan etkileri çok nadirdir. Literatürde bupropionun hiperprolak- tinemi ve yagalaktoreye neden olduğunu bildiren bir tane vaka bulunmaktadır. Biz bu yazıda depresif bozukluk tanısı ile ven- lafaksin XR başlanan sonrasında bupropion tedavisi eklenmesi ile hiperprolaktinemi ve oligomenore gelişen, bupropion teda- visinin kesilmesinin ardından kan prolactin seviyesi düzelen bir vaka sunduk.

🔖

Bu Makaleye Atıf Yap

KILIÇ, A., ÖZTÜRK, A., DEVECİ, E., KIRPINAR, İ. (2018). Development of Hyperprolactinemia Induced by the Addition of Bupropion to Venlafaxine XR Treatment. Bezmiâlem Science, Cilt: 6 - Sayı: 2, 150–152. https://ajindex.com/articles/151611

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. Wieck A, Haddad PM. Antipsychotic-induced hyperprolacti- naemia in women: pathophysiology, severity and consequences. Br J Psychiatry 2003; 182: 199-204. [CrossRef ] Bronzo MR, Stahl SM. Galactorrhea induced by sertraline (let- ter). Am J Psychiatry 1993; 150: 1269-70. [CrossRef ] Yang MS, Cheng WJ, Huang MC. Dose-related hyperprolac- tinemia induced by venlafaxine. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 733-4. [CrossRef ] Stahl SM. Noradrenaline and dophamine reuptake inhibitors, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4nd ed. Cambridge University Press; 2013. p.309-12.
  2. Arias HR, Santamaria A, Ali SF. Pharmacological and neuro- toxicological actions mediated by bupropion and diethylpro- pion. Int Rev Neurobiol 2009; 88: 223-55. [CrossRef ] Meltzer HY, Fang VS, Tricou BJ, Robertson A. Effect of anti- depressants on neuroendocrine axis in humans. Adv Biochem Psychopharmacol 1982; 32: 303-16.
  3. Bilgin A, Cam B. Bupropion associated with galactorrhea: a case report. Bull Clin Psychopharmacol 2012; 22: 153. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine trans- porters and nicotinic receptors. Mol Pharmacol 2004; 66: 675- 82. [CrossRef ] Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288: 88-92.
  4. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-56.[CrossRef ]